for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK

Latest Trade

81.02USD

Change

0.00(0.00%)

Volume

15,585

Today's Range

--

 - 

--

52 Week Range

65.25

 - 

92.64

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
81.02
Open
0.00
Volume
15,585
3M AVG Volume
202.14
Today's High
--
Today's Low
--
52 Week High
92.64
52 Week Low
65.25
Shares Out (MIL)
2,529.24
Market Cap (MIL)
204,919.10
Forward P/E
15.24
Dividend (Yield %)
3.01

Next Event

Dividend For MRK.N - 0.6100 USD

Latest Developments

More

Merck Animal Health Completes Acquisition of IdentiGEN

Merck And Hanmi Pharmaceutical Enter Into Licensing Agreement To Develop Efinopegdutide

Merck Announces Q2 Non-Gaap Earnings Per Share $1.37

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Chairman of the Board, President, Chief Executive Officer

Robert M. Davis

Executive Vice President, Global Services, Chief Financial Officer

Steven C. Mizell

Executive Vice President, Chief Human Resources Officer, Human Resources

Michael T. Nally

Executive Vice President, Chief Marketing Officer

Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

Key Stats

1.95 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

40.1K

2018

42.3K

2019

46.8K

2020(E)

48.0K
EPS (USD)

2017

3.980

2018

4.340

2019

5.190

2020(E)

5.720
Price To Earnings (TTM)
19.63
Price To Sales (TTM)
4.34
Price To Book (MRQ)
7.41
Price To Cash Flow (TTM)
14.43
Total Debt To Equity (MRQ)
111.69
LT Debt To Equity (MRQ)
94.62
Return on Investment (TTM)
15.97
Return on Equity (TTM)
12.09

Latest News

Latest News

Merck to move COVID-19 treatment into large trials, sees sales recovering this year

Merck & Co <MRK.N> on Friday said it plans to advance an antiviral treatment for COVID-19 into large studies in the coming weeks, and it forecast a more limited hit to full-year sales and profit from coronavirus lockdowns than it previously expected.

Merck plans large trials of antiviral COVID-19 drug in September

Drugmaker Merck & Co said on Friday it plans to start two large pivotal trials in September on the experimental oral antiviral COVID-19 drug it is developing with privately held Ridgeback Biotherapeutics.

Merck quarterly sales fall 7.6% as pandemic cuts doctor visits

Merck & Co Inc reported a 7.6% fall in second-quarter sales on Friday as a drop in visits to doctors' offices because of the COVID-19 pandemic hurt sales of several important drugs.

Moderna, Merck say they will not limit price of coronavirus vaccines to company cost

Moderna Inc and Merck & Co on Tuesday told a U.S. Congressional panel that they expect to profit from their coronavirus vaccines once approved, amid concerns the vaccines may not be accessible to all.

Merck CEO says raising COVID-19 vaccine hopes 'a grave disservice' - report

COVID-19 vaccines under development are not guaranteed to work and people who say to expect a vaccine before year-end are doing a "grave disservice to the public," Merck & Co Inc's <MRK.N> chief said, according to an interview published on a Harvard Business School website...

BRIEF-Merck Animal Health Receives U.S. FDA Approval Of Bravecto® Monthly Chews

* MERCK ANIMAL HEALTH RECEIVES U.S. FDA APPROVAL OF BRAVECTO® (FLURALANER) MONTHLY CHEWS

BRIEF-FDA Grants Priority Review To Merck's Supplemental Biologics License Application For Keytruda (Pembrolizumab) For Second-Line Treatment Of Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

* FDA GRANTS PRIORITY REVIEW TO MERCK’S SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR KEYTRUDA® (PEMBROLIZUMAB) FOR SECOND-LINE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

BRIEF-Merck & Co Says Deborah H. Telman Appointed As General Counsel For Organon & Co.

* MERCK ANNOUNCES APPOINTMENT OF ORGANON & CO. GENERAL COUNSEL

BRIEF-Zymeworks & Merck Sign New License Agreement

* ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS

Merck says it has agreed to supply potential COVID-19 drug Rebif to EU countries

German drugmaker Merck said on Wednesday it had agreed to supply its potential COVID-19 drug Rebif to European Union countries should orders be placed for the treatment.

BRIEF-Foghorn Therapeutics Announces Collaboration With Merck To Discover And Develop Novel Oncology Therapeutics Against Transcription Factor Target

* FOGHORN THERAPEUTICS ANNOUNCES COLLABORATION WITH MERCK TO DISCOVER AND DEVELOP NOVEL ONCOLOGY THERAPEUTICS AGAINST TRANSCRIPTION FACTOR TARGET

FDA declines to approve Merck and Eisai's liver cancer combo therapy

The U.S. drug regulator declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima as the first line of treatment in patients with liver cancer, the companies said on Wednesday.

FDA declines to approve Merck and Eisai's liver cancer combo therapy

The U.S. Food and Drug Administration on Wednesday declined to approve a combination of Merck & Co Inc's blockbuster cancer drug Keytruda and Eisai Co Ltd's Lenvima for use in previously untreated patients with liver cancer.

AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer

AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

AstraZeneca-Merck Lynparza wins EU approval for pancreatic cancer

AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynparza won approval in the European Union for treating patients with a form of pancreatic cancer.

BRIEF-Merck Announces New Analyses Showing Additional Safety, Efficacy Data For Investigational Islatravir In Combination With Doravirine In Adults With Hiv-1

* MERCK ANNOUNCES NEW ANALYSES SHOWING ADDITIONAL SAFETY AND EFFICACY DATA FOR INVESTIGATIONAL ISLATRAVIR IN COMBINATION WITH DORAVIRINE IN ADULTS WITH HIV-1 INFECTION

BRIEF-FDA Approves Merck's Keytruda For The Treatment Of Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma

* FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) THAT IS NOT CURABLE BY SURGERY OR RADIATION Source text for Eikon: Further company coverage:

BRIEF-Targovax Announces Collaborative Agreement With Merck & Co

* TARGOVAX ANNOUNCES COLLABORATION TO EVALUATE ONCOS-102 IN COMBINATION WITH KEYTRUDA[®] IN MESOTHELIOMA

BRIEF-Merck’s Keytruda Approved In China For Esophageal Squamous Cell Carcinoma

* MERCK’S KEYTRUDA (PEMBROLIZUMAB) APPROVED IN CHINA FOR SECOND-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)

BRIEF-Merck Announces V114 Met Safety, Immunogenicity Objectives In Initial Phase 3 Studies In Adults

* MERCK ANNOUNCES THAT V114, ITS INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE, MET SAFETY AND IMMUNOGENICITY OBJECTIVES IN INITIAL PHASE 3 STUDIES IN ADULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up